| Hazard Information | Back Directory | [Description]
LG 6-101 is a new propafenone-related antiarrhythmic agent with good oral activity in rats. | [Uses]
LG 6-101 is an orally active antiarrhythmic agent. LG 6-101 shows strong antiarrhythmic effects in a coronary-artery-ligation model of rats, better than Propafenone (HY-B0432). LG 6-101 also delays the occurence of ventricular premature beat (VPB)'s and has protective effects against cardiac arrest caused by aconitine[1][2]. | [in vivo]
Rats were treated with LG 6-101 (16, 32, 64, 128, 256 mg kg-1 bodyweight), LG 6-102 (4, 8, 16, 32, 64 mg kg-1 bodyweight) and propafenone (32, 64, 128, 256 mg kg-1 bodyweight) by gavage twice daily during 4 days. Both, LG 6-101 and LG 6-102 showed strong antiarrhythmic effects against arrhythmias induced on the fifth day by infusion of aconitine (10 micrograms kg-1 min-1)._x000D_
_x000D_
Reference: Naunyn Schmiedebergs Arch Pharmacol. 1992 Apr;345(4):473-7. https://pubmed.ncbi.nlm.nih.gov/1620247/ | [target]
LG 6-101 is a new propafenone-related antiarrhythmic agent with good oral activity in rats. | [References]
[1] Wascher TC, et al. LG 6-101 and LG 6-102, two new propafenone-related antiarrhythmic agents with good oral activity in rats. Naunyn Schmiedebergs Arch Pharmacol. 1992 Apr;345(4):473-7. DOI:10.1007/BF00176627
[2] Wascher TC, et al. Antiarrhythmic effects of two new propafenone related drugs. A study on four animal models of arrhythmia. Arzneimittelforschung. 1991 Feb;41(2):119-24. PMID:2043172 |
|
|